Nintedanib Accord (Nintedanib)

Nintedanib is used in fibrotic lung disorders and as part of targeted cancer regimens.

• Idiopathic pulmonary fibrosis: slows disease progression, reduces the rate of decline in forced vital capacity, and may improve quality of life for patients with this chronic fibrotic lung disorder.
• Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function parameters, limits further fibrotic remodeling, and can help preserve respiratory capacity in patients with connective‑tissue‑related lung involvement.
• Non‑small cell lung cancer (in combination therapy): enhances anti‑tumor efficacy when added to standard chemotherapy regimens, contributing to longer progression‑free intervals in eligible patients.

• Nintedanib blocks the intracellular kinase activity of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR‑1, ‑2, ‑3), platelet‑derived growth factor receptors (PDGFR‑α, ‑β) and fibroblast growth factor receptors (FGFR‑1, ‑2, ‑3). By inhibiting these pathways, the drug reduces endothelial cell proliferation, fibroblast activation, and angiogenic signaling, thereby limiting fibrotic tissue formation and tumor‑associated neovascularization. The combined inhibition curtails downstream signaling cascades such as MAPK and PI3K/AKT, which are critical for cell survival and matrix deposition.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools that may need fluid replacement.
• Nausea and vomiting: gastrointestinal upset early in treatment, often managed with anti‑emetics.
• Elevated liver enzymes: rises in ALT and AST seen in routine labs.
• Decreased appetite: reduced food intake that can cause mild weight loss.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury, including hepatitis or jaundice.
• Cardiovascular events: arterial thromboembolism, myocardial infarction or stroke.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Interstitial lung disease exacerbation: worsening of existing fibrosis or new ILD symptoms.

When prescribing Nintedanib, clinicians should observe several precautionary measures to minimize risk.

• Liver function monitoring: check ALT, AST, and bilirubin before starting and periodically during therapy.
• Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea promptly.
• Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors or inducers without dose adjustment.
• Bleeding risk: assess for anticoagulant use or history of hemorrhage before initiating treatment.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light, and store below 25 °C.

Nintedanib interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure and toxicity.
• Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce drug levels and diminish efficacy.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk when combined.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma concentrations.
• P-glycoprotein substrates (e.g., digoxin): potential for altered absorption.
• NSAIDs or aspirin: additive risk of gastrointestinal bleeding.